Table 2.

Tumoral infiltration sites and diverticulosis in patients treated with lenvatinib and developing fistulas or organ perforation

	RAI-R DTC/PDTC patients (N = 14)
	n	%
Tumor infiltration site (N = 9)
Bronchus	1	11.1
Pleura	1	11.1
Trachea	4	44.5
Trachea-esophagus	2	22.2
Bladder	1	11.1
Fistula/perforation site
Bronchus	1	7.1
Pleura	1	7.1
Trachea	4	28.6
Trachea-esophagus	2	14.3
Bladder	1	7.1
Bowel	5	35.8
Diverticulosis
Yes	2	14.3
No	12	85.7

RAI-R DTC, radioiodine-refractory differentiated thyroid cancer; PTDC, poorly differentiated thyroid cancer.